Tempus AI Insider Bartolucci Files Form 144 Share Sale Notice

Ryan M. Bartolucci, Chief Accounting Officer at Tempus AI (NASDAQ: TEM), filed a Form 144 with the SEC on May 20, 2026 [1]. The proposed sale covers 9,592 Class A shares at a total value of $566,405.34 [1]. Bartolucci is not a peripheral figure. He has been CAO since May 2021 [2] and holds an estimated 45,895 shares worth over $4 million [3]. This is not a board member selling a token position. This is the person who signs off on the numbers.

This essay argues one thing: a single Form 144 is noise, but a pattern of Form 144 filings from senior insiders at AI and tech companies, clustered on the same date, is a signal worth reading carefully. The question is not whether Bartolucci is bearish on Tempus AI. The question is what the cadence of insider pre-sale activity tells allocators about sentiment, RSU vesting cycles, and concentration risk in AI-adjacent equity positions.

The Signal: What Bartolucci Filed and What It Means

A Form 144 is a pre-sale notice. It is not a confirmation that a sale happened. Under Rule 144 of the Securities Act, affiliates of a public company must file this notice before selling restricted or control shares in the open market. The filing opens a 90-day window during which the sale can legally proceed. If the insider does not sell within that window, the notice lapses.

The mechanics matter here. Bartolucci's filing covers 9,592 Class A shares with a proposed sale value of $566,405.34 [1]. The Form 144 also lists RSU grant dates across multiple tranches [1]. RSUs, restricted stock units, are shares a company grants to employees that vest over time. When a tranche vests, the insider often sells a portion immediately to cover the tax obligation. That sale is not discretionary in the emotional sense. It is a tax event.

But here is the detail that changes the read: a separate Form 144 filed for TEM on the same date shows a prior reported sale of 2,902 Class A shares on February 19, 2026, for $171,371.31 [4]. A third TEM filing from the same cluster lists RSU grants across six separate tranches and references two 10b5-1 sales of 8,143 and 10,949 shares with proceeds shown [5]. A fourth filing, dated May 19, 2026, lists proposed dispositions from RSU tranches vesting in October 2025 and April 2026 [6].

Multiple Form 144 filings for the same company on the same date are consistent with a coordinated RSU vesting event. Several insiders vest on the same schedule. Several insiders sell to cover taxes on the same day. The filings cluster. That is structural, not conspiratorial. But knowing you are reading a cluster rather than an isolated event changes how much weight you assign to any single filing.

The 10b5-1 references in the third TEM filing [5] are particularly important. A 10b5-1 plan is a pre-scheduled selling arrangement set up in advance, typically months before the sale. It removes the insider's discretion over timing. If Bartolucci's filing is part of a 10b5-1 plan, the signal value drops significantly. The sale was decided before any recent news, earnings, or internal development. If it is not part of a 10b5-1 plan, the timing becomes a more meaningful input.

That single disclosure, whether a 10b5-1 plan exists, is the most important thing to check before drawing any conclusion from this filing.

Context: This Is Not the First Time

Bartolucci filed a prior disposal of Tempus AI shares in August 2025 [7]. That was confirmed via Tiger Brokers and corroborated by GuruFocus insider transaction records [3]. A single Form 144 is noise. A second filing from the same person, in the same role, establishes a pattern.

The CAO role deserves specific attention here. The Chief Accounting Officer is not a figurehead. This person oversees financial reporting, audit processes, and the accuracy of every number that goes into SEC filings. Bartolucci has direct visibility into cost structures, revenue recognition, and forward-looking financial health. That operational proximity to the numbers makes the timing of any discretionary sale more meaningful than a sale by a board member who attends quarterly meetings.

This is not to say the CAO selling is a red flag by default. RSU-driven selling is routine at every public company. When shares vest, the tax bill arrives immediately. Selling to cover that bill is rational and expected. The IRS does not wait for a convenient share price.

What matters is the combination of factors: the role, the prior filing history, the scale relative to total holdings, and whether the sale is pre-scheduled or discretionary. Bartolucci holds roughly 45,895 shares [3]. The proposed sale of 9,592 shares represents about 21 percent of that position. That is not a trivial trim. It is a meaningful reduction.

StockTitan also confirmed a recent RSU grant to Bartolucci of 24,000 shares [8]. That grant context matters. A large incoming RSU grant alongside a sale of vested shares is consistent with a standard tax-and-hold strategy. The insider receives new shares, sells a portion of vested shares to cover taxes, and maintains or grows net exposure. That pattern is bullish, or at least neutral, not bearish.

But the pattern only reads that way if the 10b5-1 plan confirmation is there. Without it, you are left with an inference.

The Wider Pattern on May 20

This is the third Form 144 filing I have covered from May 20, 2026 alone. Yvonne Wassenaar, a director at Arista Networks, filed a Form 144 on the same date. William Mosley, CEO of Seagate, filed for 64,584 shares on the same date. These are separate companies, separate sectors, and the same calendar date.

Corporate RSU vesting schedules often align to calendar quarters or specific grant anniversary dates. When multiple companies use similar vesting calendars, clusters of Form 144 filings appear on the same date across unrelated companies. That is a structural feature of how equity compensation works, not a signal of coordinated selling.

But it is worth knowing when you are reading a cluster. If you pull a single filing in isolation, it looks like a one-off event. If you see five filings across AI, tech, and infrastructure names on the same day, you are looking at a vesting cycle, not a sentiment shift. The correct response is to check each filing individually for 10b5-1 disclosures and to assess the role and scale of each insider's proposed sale.

Tempus AI's position in this cluster matters because of the sector. TEM operates in healthcare AI and precision medicine. The company sits at the intersection of clinical data analytics and AI infrastructure, a space drawing serious institutional allocator attention as AI revenue models mature toward enterprise contract structures. Institutional interest in healthcare AI is real and growing. The question is whether insider selling cadence at this stage of TEM's post-IPO lifecycle tells you anything about how insiders view the near-term trajectory.

TEM's total shares outstanding were listed at 174,520,978 as of May 19, 2026 [4]. The proposed sale of 9,592 shares is a rounding error at that scale. But the CAO's personal position is what matters for signal reading, not the company's total float. Against Bartolucci's estimated 45,895-share holding [3], this is a 21 percent reduction in a single filing window.

The Bear Case and Why It Probably Does Not Apply Here

Skeptics will argue that any insider selling at a post-IPO AI company is a warning sign. The logic goes: insiders know more than the market, insiders are selling, therefore the market is overpricing the stock. At a company like Tempus AI, which operates in a sector where valuations are driven partly by narrative and partly by enterprise contract momentum, that skepticism is not unreasonable.

The bear case is that Bartolucci, with direct access to cost structures and revenue recognition, is reducing exposure because the internal numbers are less compelling than the public narrative. A 21 percent reduction in a senior executive's position, absent a confirmed 10b5-1 plan, is the kind of data point that short sellers and cautious allocators flag.

The rebuttal is in the evidence. The same cluster of TEM Form 144 filings includes explicit references to 10b5-1 sales [5], and Bartolucci received a fresh 24,000-share RSU grant recently [8], which is consistent with a company retaining and incentivizing its senior accounting leadership, not one preparing for bad news. Tax-driven RSU selling alongside a new grant is a neutral-to-positive signal, not a bearish one.

Reader Relevance

If you are a portfolio manager with AI infrastructure exposure: one Form 144 from one insider is not a thesis. A pattern of filings across multiple AI and tech names in a short window is a prompt to review your position sizing. Check each company's SEC filings for 10b5-1 plan disclosures. That single data point changes how you weight the signal. Do not conflate a vesting cycle with a sentiment shift.

If you are a family office allocator evaluating TEM as part of an AI-adjacent equity basket: the CAO role sits closer to the real numbers than almost any other insider. Even if this sale is entirely RSU-driven and pre-scheduled, run a quick check on your concentration risk in TEM relative to your total healthcare AI exposure. The 10b5-1 question is the key variable. If confirmed, this is routine. If absent, it warrants a closer look at the August 2025 filing [7] alongside this one to assess whether a pattern of discretionary selling is forming.

If you are building structured products that reference AI infrastructure equities: insider selling cadence at named companies is a legitimate input into your risk review process. It does not override fundamentals. But when you are constructing a basket that includes TEM, knowing the CAO has filed two pre-sale notices within roughly nine months [1][7] is relevant to how you size the position and how you communicate concentration risk to your investors.

What to Watch Next

First, watch for 10b5-1 plan confirmation in Tempus AI's next SEC filing or in the Form 144 detail itself. That single disclosure changes the entire read on this signal. If the plan exists and was established well before May 20, 2026, this filing is routine. If no plan is disclosed, the August 2025 and May 2026 filings together form a pattern of discretionary selling that warrants closer attention.

Second, watch for additional Form 144 or Form 4 filings from other TEM insiders in the next 30 days. A second or third insider filing in a short window would shift this from routine RSU activity toward something worth investigating more carefully. One insider selling is noise. Two or three insiders selling in the same 30-day window is a different conversation.

Third, watch Q2 2026 institutional 13F filings for position changes in TEM. If large allocators are trimming while insiders are pre-filing sales, that convergence is a more meaningful signal than either data point alone. The 13F filings will cover positions as of June 30, 2026, and will be filed in mid-August. That is the next hard data point on institutional sentiment toward TEM.

The real question is not whether Bartolucci is selling. He is filing to sell. The question is whether the 10b5-1 plan exists, and if it does not, whether the timing of this filing relative to TEM's next earnings cycle tells you something the public narrative does not.